A new nomogram to predict pathologic outcome following radical prostatectomy

International Braz J Urol

Volumn 32, Issue 2, 2006, Pages 155-164

  Crippa, Alexandre ^a,b   Srougi, Miguel ^a   Dall'Oglio, Marcos F ^a   Antunes, Alberto A ^a   Leite, Katia R ^a   Nesrallah, Luciano J ^a   Ortiz, Valdemar ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Needle biopsy; Neoplasm staging; Nomograms; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NOMOGRAM; PREDICTION; PREOPERATIVE CARE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 33646695041     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382006000200005     Document Type: Article

References (35)

1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-23.
2. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA: Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer. 1995; 75: 530-8.
3. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, et al.: Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004; 171: 2215-20.
4. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, et al.: Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003; 61: 742-7.
5. San Francisco IF, Regan MM, Olumi AF, DeWolf WC: Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004; 171: 1492-9.
6. Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, et al.: Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004; 171: 200-3.
7. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167: 528-34.
8. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al.: Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 2003; 61: 589-95.
9. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al.: Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer. 2001; 91: 2196-204.
10. Tombal B, Tajeddine N, Cosyns JP, Feyaerts A, Opsomer R, Wese FX, et al.: Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer? BJU Int. 2002; 89: 543-8.
11. Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, et al.: Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002; 59: 560-5.
12. Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, et al.: Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003; 97: 1884-93.
13. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H: The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000; 163: 174-8.
14. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al.: A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003; 170: 1798-803.
15. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58: 843-8.
16. Egawa S, Suyama K, Arai Y, Matsumoto K, Tsukayama C, Kuwao S, et al.: A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J Clin Oncol. 2001; 31: 74-81.
17. Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, et al.: Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003; 21: 4568-71.
18. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110-4.
19. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, et al.: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000; 18: 1164-72.
20. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M: The TNM classification of prostate cancer. Prostate Suppl. 1992; 4: 129-38.
21. Walsh PC, Donker PJ: Impotence following radical prostatectomy: insight into etiology and prevention. 1982. J Urol. 2002; 167: 1005-10.
22. Srougi M: Radical Prostatectomy with Potency Preservation. In: Srougi M, Simon SD (ed.), Urological Cancer. Sao Paulo, Platina. 1996; pp. 357-65. [in Portuguese]
23. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep. 1966; 50: 125-8.
24. Hosmer DW, Lemeshow S: Applied logistic regression. New York, John Wiley. 1989; pp. 369.
25. Efron B, Tibshirabi RJ: Na introduction to be bootstrap. New York; Chapman & Hall. 1993; pp. 430.
26. Freedland SJ, Csathy GS, Dorey F, Aronson WJ: Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002: 167: 516-20.
27. Rioux-Leclercq NC, Chan DY, Epstein JI: Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology. 2002; 60: 666-9.
28. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166: 416-9.
29. Yan Y, Carvalhal GF, Catalona WJ, Young JD: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000; 88: 1122-30.
30. Ravery V, Chastang C, Toublanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod L: Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol. 2000; 37: 449-55.
31. Rubin MA, Mucci NR, Manley S, Sanda M, Cushenberry E, Strawderman M, et al.: Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? J Urol. 2001; 165: 114-8.
32. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, et al.: Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology. 2000; 56: 730-4.
33. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM: Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol. 2001; 25: 657-60.
34. Chan TY, Partin AW, Walsh PC, Epstein JI: Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000; 56: 823-7.
35. Grober ED, Tsihlias J, Jewett MA, Sweet JM, Evans AJ, Trachtenberg J, et al.: Correlation of the primary Gleason pattern on prostate needle biopsy with clinicopathological factors in Gleason 7 tumors. Can J Urol. 2004; 11: 2157-62.